We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 10, 2020

First-in-Class ATR Inhibitor as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
J. Clin. Oncol 2020 Jun 22;[EPub Ahead of Print], TA Yap, B O'Carrigan, MS Penney, JS Lim, JS Brown, MJ de Miguel Luken, N Tunariu, R Perez-Lopez, DN Rodrigues, R Riisnaes, I Figueiredo, S Carreira, B Hare, K McDermott, S Khalique, CT Williamson, R Natrajan, SJ Pettitt, CJ Lord, U Banerji, J Pollard, J Lopez, JS de Bono

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading